MICs of imipenem, cefoxitin, cefmetazole, and amoxicillin-clavulanic acid were determined against 100 strains of Mycobacteriumfortuitum and 200 strains ofMycobacterium chelonae. Imipenem and cefmetazole were more active against M. fortuitum than cefoxitin was, and imipenem (which inhibited 39% of strains at 8 ,ug/ml) was the only beta-lactam active against M. chelonae subsp. chelonae.
Rapidly growing mycobacteria cause a variety of infections, the majority of which involve skin and soft tissues (22) . Antimicrobial therapy based on in vitro susceptibilities combined with surgical debridement are the indicated therapy for patients with serious cutaneous disease (9, 20) . Long-term drug therapy of 3 to 6 months is usually needed (20) . Amikacin is the most common drug used for serious disease, often in combination with cefoxitin (8, 9, 20) . Because of toxicity (amikacin) and a relatively short half-life (cefoxitin), there has been continued interest in other potential drugs for therapy.
We chose to compare three beta-lactams (cefmetazole, imipenem, and amoxicillin-clavulanic acid) with cefoxitin for their in vitro activities against the common pathogenic species of rapidly growing mycobacteria, Mycobacterium fortuitum and Mycobacterium chelonae, after preliminary studies showed that the drugs have therapeutic potential (5, 17) .
MICs were determined by using broth microdilutions with cation-supplemented Mueller-Hinton broth as described by Swenson et al. (16) . Twofold dilutions of cefoxitin, cefmetazole, imipenem, and amoxicillin-clavulanic acid (2:1 ratio) were prepared and added to 96-well plates by using the Mini-Quick Spense II system (Dynatech Laboratories, Chantilly, Va.). Plates were inoculated with disposable inoculators with a dilution designed to obtain a final well concentration of 104 to 105 CFU/ml. The plates were covered, sealed in plastic bags, and incubated in room air at 30°C for 3 days. Quality control was performed by using Staphylococcus aureus ATCC 29213, Escherichia coli ATCC 25922, E. coli ATCC 35218 (clavulanic acid), and M. fortuitum ATCC 6841. Moderately susceptible breakpoints for imipenem (8 jig/ml) and amoxicillin-clavulanic acid (16/8 ,ug/ml) were the moderately susceptible breakpoints of the National Committee for Clinical Laboratory Standards (NCCLS) for aerobic bacteria (13) . An MIC of 32 ,ug/ml rather than 16 ,ug/ml (the latter being the NCCLS breakpoint) has been used as the moderately susceptible breakpoint for cefoxitin against the rapidly growing mycobacteria (17, 20) .
Although not yet approved by NCCLS, the proposed moderately susceptible breakpoint for cefmetazole is also 32 jig/ml (10 Laboratory of the University of Texas between 1987 and 1990 were tested. Identification to the species level was performed by standard methods (14, 21) , and identification to the subspecies level was by carbohydrate utilization tests and/or drug susceptibility patterns (14, 15 (1, 7, 9, 16, 17) and most isolates of M. chelonae subsp. abscessus (1, 16, 17) , although the usual modal MIC for both organisms is 32 pug/ml, which is in the moderately susceptible category (as defined for these organisms) (10, 17) . Results for cefoxitin from the current study were comparable.
Cefmetazole, like cefoxitin, is a 7-ot-methoxy cephalosporin or cephamycin, but the former has approximately 20% higher peak levels in serum and a longer half-life (90 versus 50 min) (11), which may allow for longer dosing intervals. The current study showed that cefmetazole has two-to fourfold greater activity than cefoxitin against M. fortuitum biovar. fortuitum, supporting similar findings in two previous studies by Cynamon and Palmer (5) (19) .
A previous study of cefmetazole against 20 strains of M. chelonae by Casal et al. (4) showed that it inhibits 40% of the strains at 16 ,ug/ml. The subspecies of the isolates was not determined. The current study showed that the activities of cefoxitin and cefmetazole against M. chelonae are comparable, but they have activities at clinically achievable levels only against M. chelonae subsp. abscessus. The isolates of M. chelonae subsp. chelonae were all highly resistant to 2 2 100
a The concentration listed is that for amoxicillin.
both cephamycins (MICs, >128 jig/ml). Previous studies of cefoxitin-resistant isolates of the unnamed third biovariant complex of M. fortuitum showed that they are also crossresistant to cefmetazole (19) . Imipenem was the most active beta-lactam studied, inhibiting 100% of M. fortuitum isolates, 57% of M. chelonae subsp. abscessus isolates, and 39% of M. chelonae subsp. chelonae isolates at 8 ,ug/ml. The MICs for M. fortuitum were comparable to those given in prior studies by Cynamon and Palmer (5) (12 strains) and Swenson et al. (17) (17 strains). The same MICs for 50% of isolates tested (2 ,ug/ml) and MICs for 90% of isolates tested (4 ,ug/ml) for imipenem observed here for the isolates of M. fortuitum biovar. fortuitum have been reported for 75 isolates of the unnamed third biovariant complex of M. fortuitum (18) . One-third of these latter isolates were resistant to cefoxitin. Imipenem is the only known beta-lactam with activity against M.' chelonae subsp. chelonae.
Isolates of M. fortuitum biovar. fortuitum have a single chromosomal P-lactamase (19) which is partially susceptible in vitro to clavulanic acid (6, 12) . Previous studies (2, 6, 12) showed that clavulanic acid produces a two-to fourfold decrease in MICs for M. fortuitum when compared with that of amoxicillin alone. The current study showed an MIC for 90% of strains of 16/8 p.g of the amoxicillin-clavulanic acid combination (2:1 ratio) per ml. By using the pe'ak achievable level in serum of 2 ,ug of clavulanic acid per ml as a breakpoint, however, only 18% of strains were susceptible. Imipenem was used successfully in the monotherapy of a case of M. chelonae lung disease (MIC, 8 ,ug/ml) (23) . No information is available on the clinical usefulness of amoxicillin-clavulanic acid and cefmetazole. However, both imipenem and cefmetazole have as good a potential for therapy as that of the only other proven beta-lactam, cefoxitin, and all three drugs have sufficient in vitro activities to warrant clinical evaluation.
